Description: <b>Flavonoid glycoside</b>. Responsible for the bitterness of grapefruit.<br>
Naringin is a flavonoid glycoside predominantly found in citrus fruits such as grapefruit and oranges. It is known for its antioxidant, anti-inflammatory, and potential anticancer properties.<br>
It is hydrolyzed in vivo to naringenin, which exhibits antioxidant and anti-inflammatory activities and modulates signaling pathways (e.g., Nrf2 and NF-κB). In preclinical cancer models, naringin/naringenin is associated with cell-cycle arrest, apoptosis, and reduced invasion/metastasis, often linked to upstream modulation of survival pathways (PI3K/AKT) and stress MAPKs. Oral systemic exposure is limited due to metabolism and conjugation.<br>
-Antioxidant Activity<br>
-Induction of Apoptosis<br>
-Cell Cycle Arrest (often G1 or G2/M)<br>
-Anti-inflammatory Effects<br>
<br>
-**a natural bioenhancer(effects vary) and reported to enhance the bioavailability of drugs by inhibiting cytochrome P450 (CYP3A4 especially grape fruit juice) and P-glycoprotein (P-gp). Naringin/naringenin can inhibit CYP3A4 and P-glycoprotein, contributing to grapefruit–drug interactions and potentially increasing exposure of certain medications.<br>
-Usually paired with other bioflavonoids such as quercetin, hesperidin and rutin.<br>
<br>
-Mainly obtained from grapefruit<br>
-Including enhanced solubility, improved bioavailability and targeted delivery.<br>
-Antioxidant<br>
-Inhibition of CYP19(weak/modest). Naringin suppresses the PI3K/AKT signalling pathway<br>
-Wnt/β-catenin, PI3K/Akt, NF-ĸB, and TGF-β pathways<br>
-Up-regulation of adenosine monophosphate-activated protein kinase (AMPK), and inhibition of gluconeogenesis<br>
-Antioxidant effects, by modulating reactive oxygen species (ROS) levels and increasing superoxide dismutase (SOD)<br>
-Naringenin can reduce carcinogenesis through pleiotropic processes such as antioxidative, apoptotic-inducing ROS generation, and cell cycle arrest<br>
-Revealed new mechanisms underlying the hypolipidemic effects of naringin and naringenin, including regulation of lipid digestion, reverse cholesterol transport, and low-density lipoprotein receptor expression<br>
-Low bioavailability (approximately 8.8%) when administered orally. Bioavailability: citrus flavonoid glycosides are hydrolyzed in the gut; systemic plasma levels are often much lower than in vitro MICs.<br>
<br>
<!-- Naringin — Time-Scale Flagged Pathway Table -->
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Nrf2/ARE antioxidant response</td>
<td>Stress adaptation modulation (context-dependent)</td>
<td>Nrf2 ↑; antioxidant enzymes ↑</td>
<td>R, G</td>
<td>Endogenous antioxidant upshift</td>
<td>Naringin and its aglycone naringenin are widely reported to activate Nrf2, elevate HO-1 and other antioxidant defenses, and reduce oxidative injury in many models.</td>
</tr>
<tr>
<td>2</td>
<td>NF-κB inflammatory signaling</td>
<td>NF-κB ↓; pro-inflammatory cytokines ↓ (reported)</td>
<td>Inflammation tone ↓</td>
<td>R, G</td>
<td>Anti-inflammatory signaling</td>
<td>Consistent evidence shows naringin/naringenin reduces pro-inflammatory signaling and cytokine expression in tumor and non-tumor contexts.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K/AKT/mTOR survival axis</td>
<td>PI3K/AKT ↓ (reported; model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Growth/survival modulation</td>
<td>Modulation of survival pathways is observed in various cancer‐cell studies, but effects vary by cell type and context.</td>
</tr>
<tr>
<td>4</td>
<td>Cell cycle control (Cyclins/CDKs)</td>
<td>Cell-cycle arrest ↑ (G1/S or G2/M; reported)</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Often reported as reduced proliferation and cell cycle arrest following upstream signaling changes.</td>
</tr>
<tr>
<td>5</td>
<td>Intrinsic apoptosis (mitochondrial/caspase linked)</td>
<td>Apoptosis ↑; caspase activation ↑ (reported)</td>
<td>↔</td>
<td>G</td>
<td>Execution of cell death</td>
<td>Observed in many in vitro models, usually downstream of signaling modulation and stress pathways.</td>
</tr>
<tr>
<td>6</td>
<td>MAPK re-wiring (ERK / JNK / p38)</td>
<td>MAPK modulation (context-dependent)</td>
<td>↔</td>
<td>P, R, G</td>
<td>Stress/mitogenic signaling adjustment</td>
<td>MAPK effects vary by assay and cell type; avoid fixed up/down arrows without a specific citation.</td>
</tr>
<tr>
<td>7</td>
<td>Invasion / metastasis programs (MMPs/EMT)</td>
<td>MMPs ↓; migration/invasion ↓ (reported)</td>
<td>↔</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Downstream phenotype changes reported in some models; linked to NF-κB/MAPK modulation.</td>
</tr>
<tr>
<td>8</td>
<td>Angiogenesis signaling (VEGF & related)</td>
<td>Angiogenic outputs ↓ (reported)</td>
<td>↔</td>
<td>G</td>
<td>Anti-angiogenic support</td>
<td>Later phenotype outcomes; direction is often model-dependent.</td>
</tr>
<tr>
<td>9</td>
<td>Reactive oxygen species modulation</td>
<td>Redox buffering; ROS direction variable</td>
<td>↔</td>
<td>P, R, G</td>
<td>Redox modulation (context-dependent)</td>
<td>Naringin is classically antioxidant; ROS changes in cancer models vary and are not reliably pro-oxidant under typical conditions.</td>
</tr>
<tr>
<td>10</td>
<td>Bioavailability / metabolism constraint</td>
<td>Systemic exposure limited; rapid metabolism/conjugation</td>
<td>—</td>
<td>—</td>
<td>Translation constraint</td>
<td>Naringin’s glycoside form is hydrolyzed to naringenin; phase II conjugates circulate. Native systemic levels are often low compared with in vitro effective concentrations.</td>
</tr>
</table>
<p><b>Time-Scale Flag (TSF):</b> P / R / G</p>
<ul>
<li><b>P</b>: 0–30 min (rapid biochemical/signaling interactions)</li>
<li><b>R</b>: 30 min–3 hr (acute signaling and transcription modulation)</li>
<li><b>G</b>: >3 hr (gene-regulatory adaptation and phenotype outcomes)</li>
</ul>